HOPA 2018 Highlights

Based on the available data, the question still remains as to whether nivolumab plus ipilimumab provides a significant OS benefit compared with nivolumab monotherapy.

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Dr Seddon provided attendees with an overview of FLT3-mutated AML, including currently available treatments, mechanisms of resistance, and future directions.

PD-L1 is decidedly unique when compared with other biomarkers currently used in oncology, and the impact of PD-L1 expression has been demonstrated in numerous clinical scenarios.

Results 1 - 3 of 3